A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis

ClinicalTrials.gov ID: NCT00703573

Public ClinicalTrials.gov record NCT00703573. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 16, 2026, 9:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of 2 Doses of S-777469 (400 mg BID and 800 mg BID) in Patients With Atopic Dermatitis

Study identification

NCT ID: NCT00703573
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Shionogi; Industry
Enrollment: 209 participants

Conditions and interventions

Conditions

Atopic Dermatitis

Interventions

Placebo Drug
S-777469 400 mg Drug
S-777469 800 mg Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 30, 2008
Primary completion: Apr 30, 2009
Completion: Nov 30, 2009
Last update posted: May 7, 2018

2008 – 2009

United States locations

U.S. sites: 33
U.S. states: 19
U.S. cities: 31

Facility	City	State	ZIP	Site status
Not listed	Hot Springs	Arkansas	71913	—
Not listed	Los Angeles	California	90045	—
Not listed	Oceanside	California	92056	—
Not listed	Riverside	California	92506	—
Not listed	Denver	Colorado	80210	—
Not listed	Coral Gables	Florida	33134	—
Not listed	West Palm Beach	Florida	33401	—
Not listed	Alpharetta	Georgia	30022	—
Not listed	Boise	Idaho	83704	—
Not listed	Arlington Heights	Illinois	60005	—
Not listed	Evansville	Indiana	47713	—
Not listed	South Bend	Indiana	46617	—
Not listed	Fridley	Minnesota	55432	—
Not listed	Omaha	Nebraska	68144	—
Not listed	Berlin	New Jersey	08009	—
Not listed	Paramus	New Jersey	07652	—
Not listed	Stony Brook	New York	11790	—
Not listed	Lake Oswego	Oregon	97035	—
Not listed	Portland	Oregon	97210	—
Not listed	Portland	Oregon	97223	—
Not listed	Portland	Oregon	973239	—
Not listed	Philadelphia	Pennsylvania	19104	—
Not listed	Johnston	Rhode Island	02919	—
Not listed	Goodlettsville	Tennessee	37072	—
Not listed	Knoxville	Tennessee	37934	—
Not listed	Austin	Texas	78759	—
Not listed	College Station	Texas	77845	—
Not listed	Dallas	Texas	75230	—
Not listed	Houston	Texas	77058	—
Not listed	San Antonio	Texas	78229	—
Not listed	West Jordan	Utah	84088	—
Not listed	Lynchburg	Virginia	24501	—
Not listed	Norfolk	Virginia	23507	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00703573, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 7, 2018 · Synced May 16, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00703573 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →